XML 69 R39.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Organization and Significant Accounting Policies, Cash, Cash Equivalents and Investments (Details) $ in Thousands | 12 Months Ended
--- | ---
Dec. 31, 2021 USD ($) Company | Dec. 31, 2020 USD ($) Investment | Dec. 31, 2019 USD ($)
Cash, Cash Equivalents and Investments [Abstract] |  |  |
Number of publicly held companies in which there is an equity ownership interest of less than 20% | Company | 3 |  |
Number of privately held companies in which there is an equity ownership interest of less than 20% | Company | 7 |  |
Number of investments in privately held companies that were revalued | Investment |  | 3 |
Gain on investment | $ 10,103 | $ 16,540 | $ 192
Dynacure [Member] |  |  |
Cash, Cash Equivalents and Investments [Abstract] |  |  |
Gain on investment |  | 6,300 |
Suzhou-Ribo [Member] |  |  |
Cash, Cash Equivalents and Investments [Abstract] |  |  |
Gain on investment |  | 3,000 |
Aro Biotherapeutics [Member] |  |  |
Cash, Cash Equivalents and Investments [Abstract] |  |  |
Gain on investment |  | $ 5,500 |

X
- Definition Number of investments in privately-held companies that were revalued since the companies sold additional equity securities. + References No definition available. + Details
Name: | ions_NumberOfInvestmentsInPrivatelyHeldCompaniesThatWereRevalued
Namespace Prefix: | ions_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of privately-held companies, in which the entity has an equity ownership interest of less than 20%, with which it conducts business. These are accounted for under the cost method. + References No definition available. + Details
Name: | ions_NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment
Namespace Prefix: | ions_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of publicly-held companies, in which the entity has an equity ownership interest of less than 20%, with which it conducts business. These are accounted for at fair value. + References No definition available. + Details
Name: | ions_NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment
Namespace Prefix: | ions_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of realized and unrealized gain (loss) on investment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 50 -Paragraph 10 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=123581744&loc=d3e27405-111563 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.7(c),9(a)) -URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227 Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585 + Details
Name: | us-gaap_GainLossOnInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=ions_DynacureSasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=ions_SuzhouRiboLifeScienceCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=ions_AroBiotherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |